Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Conmed (CNMD) Liabilities and Shareholders Equity (2016 - 2025)

Conmed (CNMD) has disclosed Liabilities and Shareholders Equity for 16 consecutive years, with $2.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity rose 0.85% year-over-year to $2.3 billion, compared with a TTM value of $9.3 billion through Dec 2025, up 0.62%, and an annual FY2025 reading of $2.3 billion, up 0.85% over the prior year.
  • Liabilities and Shareholders Equity was $2.3 billion for Q4 2025 at Conmed, roughly flat from $2.3 billion in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $2.3 billion in Q2 2025 and bottomed at $1.7 billion in Q1 2021.
  • Average Liabilities and Shareholders Equity over 5 years is $2.2 billion, with a median of $2.3 billion recorded in 2023.
  • The sharpest move saw Liabilities and Shareholders Equity surged 30.67% in 2022, then dropped 1.6% in 2024.
  • Year by year, Liabilities and Shareholders Equity stood at $1.8 billion in 2021, then soared by 30.1% to $2.3 billion in 2022, then increased by 0.11% to $2.3 billion in 2023, then increased by 0.27% to $2.3 billion in 2024, then increased by 0.85% to $2.3 billion in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for CNMD at $2.3 billion in Q4 2025, $2.3 billion in Q3 2025, and $2.3 billion in Q2 2025.